The World Health Organization reports that obesity affects one in eight people globally, making it a major public issue. Yet obesity is not just about diet, exercise, and genes — something else must be afoot. Recently, evidence has pointed to an invisible but powerful culprit: dioxins and dioxin-like polychlorinated diphenyls (DL-PCBs), according to “Association Between...
Recently I was watching a couple of movies from the 1970s; one was a drama filmed in New York City and the other was a documentary filmed in California. There were plenty of random shots of people in streets as well as crowds at various events throughout both. However, one thing about both movies that... Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized weight loss management, and researchers are now exploring how these medications can further transform obesity care and offer new possibilities for long-term weight management, according to a recent review article published in Endocrinology. Authors Lauren A. Jones and Daniel I. Brierley, PhD, both of the Centre for Cardiovascular...
Kids On the Move: Protecting Future Generations from Obesity
Leading pediatric endocrinologist and recipient of the Endocrine Society’s 2025 Outstanding Leadership in Endocrinology Laureate Award, Ilene Fennoy, MD, talks with Endocrine News about the potential of GLP-1s and long-term solutions for childhood obesity. She says a good place to start is creating more programs in schools to help kids eat better and incorporate more...
Weighing In: Making Obesity Treatment More Effective and Accessible by 2030
Endocrine News speaks to the participants of the ENDO 2025 symposium “Future Developments and Challenges in Obesity Treatment: Where Will We Stand at ENDO 2030?” who discuss the future of treating this formidable condition. This July, the year’s biggest event in endocrinology happens in San Francisco, Calif. Although every ENDO is special, ENDO 2025...Harsh Realities: How Treating Obesity Across the Lifespan Continues to Evolve
Fatima Cody Stanford, MD, MPH, MPA, MBA, takes the lessons she learned growing up in Atlanta serving her community and applies them to her work treating obesity. In July, she’ll give the plenary presentation at ENDO 2025, “Changing the Game of Obesity Care Across Lifespan: Policies, Diets, and Drug Innovation,” offering attendees a comprehensive overview...
Yo-Yo Dieting May Significantly Increase Kidney Disease Risk in People with Type 1 Diabetes
Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI) and other traditional risk factors, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Yo-yo dieting is defined...
All the Rage: Combatting Counterfeit Weight-Loss and Diabetes Drugs
As online ads abound for diabetes and obesity medications, endocrinologists should be prepared to talk to patients who may be attracted to GLP-1 drug lookalikes and supplements from questionable sources. GLP-1 agonists are a cultural phenomenon. Celebrities and social media influencers hyping the drugs’ weight-loss success has led to demand outstripping supply, resulting in shortages...
